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Abstract
Curative and prophylactic therapy for Pneumocystis jiroveci pneumonia relies mainly on cotrimoxazole, an association of trimethoprim
and sulfamethoxazole (SMX). SMX inhibits the folic acid pathway through competition with para-aminobenzoic acid (pABA), one of the
two substrates of the dihydropteroate synthase (DHPS), a key enzyme in de novo folic acid synthesis. The most frequent non-synony-
mous single nucleotide polymorphisms (SNPs) in P. jiroveci DHPS are seen at positions 165 and 171, the combination leading to four
possible different genetic alleles. A number of reports correlate prophylaxis failure and mutation in the P. jiroveci DHPS but, because of
the impossibility of reliably cultivating P. jiroveci, the link between DHPS mutation(s) and SMX susceptibility is not definitively proven. To
circumvent this limitation, the yeast Saccharomyces cerevisiae was used as a model. The introduction of the P. jiroveci DHPS gene, with or
without point mutations, directly amplified from a clinical specimen and cloned in a centromeric plasmid into a DHPS-deleted yeast
strain, allowed a fully effective complementation. However, in the presence of SMX at concentrations >250 mg/L, yeasts complemented
with the double mutated allele showed a lower susceptibility compared with strains complemented with either a single mutated allele
or wild-type alleles. These results confirm the need for prospective study of pneumocystosis, including systematic determination of the
DHPS genotype, to clarify further the impact of mutations on clinical outcome. Additionally, the S. cerevisiae model proves to be useful
for the study of still uninvestigated biological properties of P. jiroveci.
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Introduction
Pneumocystis pneumonia (PCP) caused by Pneumocystis jiroveci
remains an important opportunistic infection affecting immu-
nocompromised patients such as organ transplant patients,
cancer patients and, especially, human immunodeficiency
virus (HIV)-infected patients [1–3]. Although the incidence of
PCP has declined in HIV patients due to the introduction of
highly active antiretroviral therapy [4], PCP still reveals HIV
infection in >40% of cases in France [5], and remains an
important cause of mortality [6].
The drug of choice for both treatment and prophylaxis of
PCP is cotrimoxazole, a combination of sulfamethoxazole
(SMX) and trimethoprim [7]. Sulfa drugs such as SMX act on
the folic acid synthesis (FAS) pathway and deplete cells of
folates, which are essential for growth. SMX activity occurs
by competing with para-aminobenzoic acid (pABA) in a reac-
tion catalysed by dihydropteroate synthase (DHPS) that leads
to the formation of a precursor of folinic acid [8]. As is the
case in Saccharomyces cerevisiae, the P. jiroveci FAS protein
is a multidomain protein responsible for DHPS activity, in
conjunction with other enzyme activities also involved in the
de novo FAS pathway [9]. Most common non-synonymous
mutations single nucleotide polymorphisms (SNPs) in the
P. jiroveci DHPS gene are located at nucleotide positions 165
(A–G) and 171 (C–T), causing amino acid substitutions at
codon 55 (Thr to Ala) and 57 (Pro to Ser) in a highly
conserved region of one of the putative active sites of the
enzyme [10,11]. Likewise, similar point mutations in equiva-
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lent positions have been shown to cause sulfa resistance in
pathogens such as Plasmodium falciparum [12], Toxoplasma
gondii [13], Streptococcus pneumonia [14] and Escherichia coli
[15]. Several studies have demonstrated a significant associa-
tion between sulfa and sulfone prophylaxis and the emer-
gence of DHPS gene mutations in P. jiroveci [16–18].
Because there is still no reliable culture system for P. jiroveci,
resistance studies based upon in vitro drug susceptibility testing
cannot be performed. In this study, S. cerevisiae was used as a
model to better understand the relationship between DHPS
gene mutations and sulfa drug susceptibility. Although phyloge-
netically distant, both species are members of the phylum Asc-
omycota and contain similar DHPS genes. While similar
studies have been done using site mutagenesis targeting the
S. cerevisiae DHPS gene [19,20], we show here that the P. jiro-
veci DHPS can complement the S. cerevisiae deletion mutant,
and then tested DHPS alleles, with or without point muta-
tion(s), collected directly from clinical samples. Using this
strategy, we demonstrate that a decrease in susceptibility to
SMX is associated with the double mutated genotype.
Materials and Methods
Reagents were purchased from Sigma (Lyon, France) excepted
when specified.
Strains and growth
Molecular cloning and plasmid amplification were done in the
E. coli strain DH5a (Gibco, Cergy Pontoise, France). The
growth medium used was Luria-Bertani (LB) broth (1% tryp-
tone, 0.5% yeast extract, 0.5% NaCl). Cells were made com-
petent by calcium chloride treatment, and transformants
were selected in LB supplemented with 100 mg/L of ampicil-
lin (LB-Amp). Saccharomyces cerevisiae yeast strains used in
this study derived from YH1 (mata leu2-3, 112trp1 tup1 ura
3-52) [21]. Yeasts were grown in YEPD medium (1% yeast
extract (Difco), 2% peptone (Difco), 2% glucose). The S. cere-
visiae DHPS-deficient strain EHY1 (mata leu2-3, 112trp1 tup1
ura 3-52 DHPS::LEU2) was grown in YEPD supplemented
with 100 mg/L of folinic acid [22].
Cloning P. jiroveci DHPS gene into the yeast expression
vector pCM189
Bronchoalveolar lavage fluid samples were obtained from
patients with a diagnosis of PCP confirmed by Giemsa staining
and indirect immunofluorescence (MonoFluo kit P. carinii; Bio-
Rad, Marnes-la-Coquette, France). DNA was extracted with a
QiaGen Mini kit (Qiagen, Courtaboeuf, France) and P. jiroveci
DHPS genotype was determined using a PCR-RFLP method
previously described [23]. The four DHPS genotypes: WW
(wild type in positions 165 and 171), WM (wild type in 165
and mutated in 171), MW (mutated in position 165 and wild
type in 171) and MM (mutated in positions 165 and 171) were
obtained for this study. For cloning, the P. jiroveci DHPS gene
was amplified by a nested PCR protocol using the primers
Pj-DHPS-F1and Pj-DHPS-R1 for the first PCR and hybrid
primers Pj-DHPS-F2 and Pj-DHPS-R2 containing the BglII
restriction enzyme site for the second PCR (Table 1). The
sequence of P. carinii f. sp. hominis hydroxymethyl-dihydrop-
terin pyrophosphokinase/dihydropteroate synthase gene
(GenBank accession AF139132) was used to design the prim-
ers. Primers were selected to amplify the complete ORF of
the DHPS domain (48 nt upstream the start codon to 61 nt
downstream the stop codon). Cycles of amplification were as
follows: 94C for 5 min, then five cycles at 94C for 30 s,
55C for 1 min and 72C for 1 min followed by 25 cycles at
94C for 30 s, 50C for 1 min and 72C for 1 min. For the
second round of PCR, the protocol was ten cycles at 92C for
30 s, 52C for 1 min and 72C for 1 min followed by 25 cycles
at 92C for 30 s, 42C for 1 min and 72C for 1 min. The
resulting product (834 bp) was digested with BglII, purified
using a QiaGen Mini kit, and cloned into the yeast centromeric
vector pCM189 [24] previously digested with BamHI.
This plasmid is characterized by the presence of the Ura3
gene and a tet promoter, repressed by doxycycline, behind the
multiple-cloning site. Cloning was done for each of the four
P. jiroveci DHPS genotypes to produce WW-, WM-, MW-,
MM-pCM189-PjDHPS. As a control, the DHPS gene of S. cerevi-
siae was amplified using primers Sc-DHPS-F and Sc-DHPS-R
(Table 1), and then similarly cloned to produce pCM189-
ScDHPS. Vectors were then introduced into E. coli by electro-
poration transformation [25]. The insertion of DHPS into the
plasmid was verified by PCR on colonies selected on LB-Amp
plates using the Seq4 and Seq8 primers (Table 1). Positive
transformants were then grown in LB-Amp broth overnight at
37C. Plasmids were then extracted using a JetSTAR kit
TABLE 1. PCR primers used in this study
Name Sequences 5¢ ﬁ 3¢ Origin
Ahum GCGCCTACACATATTATGGCCATTTTAAATC [23]
Bhum CATAAACATCATGAACCC [23]
Pj-DHPS-F1 GGATTACCTATAGTTTCTTATC This study
Pj-DHPS-R1 GCAAAATTACAATCAACCAAAG This study
Pj-DHPS-F2 GAAGATCTTCCCTGGTATTAAACCAGTTTTGC This study
Pj-DHPS-R2 GAAGATCTTCCAATTCAATAAACTCCTTTCC This study
Sc-DHPS-F CGCGGATCCCGTAGTGGTGTGGAGCCT This study
Sc-DHPS-R CGCGGATCCCACTTGTTTCCTCCCTTGG This study
Seq-4 CAGGTTGTCTAACTCCTTCCTTTTCG [24]
Seq-8 GAGCTCGGTACCCTATGGCA [24]
BglII restriction sites used for cloning are underlined.
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(Qbiogen, Illkirch, France). The product (1834 bp) was gel-
purified using a Qiagen Gel extraction kit (Qiagen) and intro-
duced into the S. cerevisiae EHY1 strain by lithium acetate pro-
tocol transformation [26]. EHY1 transformants were selected
in minimal medium plates (0.65% yeast nitrogen base (YNB)
medium without amino acids, 2% glucose) supplemented with
20 mg/L tryptophan and 100 mg/L thymidine monophosphate.
In order to eliminate the presence of other mutations in the
amplified sequence, alleles used for transformation were
sequenced at this step by direct sequencing of amplicons
obtained by PCR colony using primers Pj-DHPS-F2 and Pj-
DHPS-R2. The role of the plasmid in the change of phenotype
was checked by plating transformants on media with and with-
out doxycycline (100 mg/L).
Sulfa drug resistance assays
As a first experiment, the susceptibility of S. cerevisiae to
SMX was checked by plating tenfold serial suspensions of
YH1 strain (102–105 CFU/mL) onto YNB, added with
increasing SMX (ICN Biomedicals Inc., Warrenale, PA, USA)
concentrations prepared in 70% ethanol from 50 to
1000 mg/L. Complemented yeasts were further tested simi-
larly. The reversion of the phenotype was checked by the
addition of 100 mg/L folinic acid to the medium. The plates
were evaluated after 2 days’ incubation at 30C.
To evaluate further the in vitro susceptibility of con-
structed strains to SMX, a liquid medium assay was also
used. Briefly, 2 · 108 cells, pre-cultured overnight in YNB
medium supplemented with 20 to SMX tryptophan and 100
to SMX thymidine monophosphate, were cultured in this
medium, added with increasing concentrations of SMX, from
0 to 3 mg/mL, in a 96-U-shaped-well microplate. Absorbance
at 595 mm was measured after 48 h of incubation at 30C.
Each experiment was done in triplicate.
Results
Effect of SMX on S. cerevisiae yeast
To establish the validity of our yeast model system, the
effect of SMX on the growth of S. cerevisiae strain YH1,
which has a functional DHPS, was confirmed. As shown in
Fig. 1, YH1 (inoculum £103 cells/mL) was sensitive to SMX,
with an inhibition of growth especially noticeable when the
concentration of SMX reached 250 mg/L and complete inhi-
bition at concentrations of SMX >1000 mg/L. In the presence
of folinic acid, the growth was restored to a level similar to
that observed in the absence of SMX, suggesting an uptake
of folinic acid by the yeasts. The same results were obtained
when pABA at 2 mg/L was added instead of folinic acid. No
growth was observed for S. cerevisiae strain EHY1 in the
absence of exogenous folinic acid.
Cloning of P. jiroveci DHPS in EHY1 and complementation
tests
To test the complementation of the DHPS-deleted EHY1
strain by P. jiroveci DHPS, the yeasts were transformed with
either WW-pCM189-PjDHPS or pCM189-ScDHPS as a con-
trol, and plated in parallel onto YNB, with or without exoge-
nous folinic acid (Fig. 1). Both constructed plasmids allowed
the EHY1 strain to grow normally without the need of exog-
enous folinic acid. Addition of doxycycline induced an inhibi-
tion of growth, supporting the fact that normal growth is
restored by the plasmid-borne gene controlled by the tet-off
promoter (Fig. 2). The addition of folinic acid abolished the
growth inhibition afforded by doxycycline and restored a
wild-type phenotype (data not shown).
Double mutation in P. jiroveci DHPS gene influences SMX
susceptibility of S. cerevisiae complemented yeast
Whatever the P. jiroveci DHPS genotype, transformants were
found to be able to grow on minimal medium without addition
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FIG. 1. Susceptibility of Saccharomyces cerevisiae strains to sulfameth-
oxazole (SMX) and reversion of the activity by exogenous folinic
acid. Log serial dilutions of yeast cell suspensions. Yeast strains (A)
YH1 [functional dihydropteroate synthase (DHPS)]; (B) EHY1
(DHPS-deficient) transformed with pCM189-wild type Pneumocystis
jiroveci DHPS; (C) EHY1 transformed with pCM189-S. cerevisiae
DHPS. Plates were photographed after 2 days’ incubation at 30C.
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of folinic acid or pABA and therefore express a functional
DHPS. In order to examine the effect of P. jiroveci DHPS muta-
tions of SMX resistance, the in vitro susceptibility of EHY1
transformed with pCM189 harbouring one of the four
genotypes of P. jiroveci DHPS was compared. As shown in
Fig. 2, a single mutation at either position 165 or 171 did not
induce any change in susceptibility to SMX, compared with
wild-type DHPS of P. jiroveci or the parent strain YH1 with a
functional DHPS. In contrast, EHY1 expressing the double
mutant P. jiroveci DHPS appeared less susceptible to SMX than
other constructed strains with either a wild-type or single
mutation profile, and grew in the presence of SMX at 250 mg/
L. In a microdilution assay with SMX concentrations of 1.5 mg/
mL, growth of yeast strains complemented with either wild-
type or single mutated P. jiroveci-DHPS was reduced by 72–
75%, whereas double mutation was associated with a growth
reduction of only 10% (Fig. 3). Indeed, SMX concentration as
high as 3 mg/mL had only a marginal effect (11.6% reduction)
on the growth of this strain. In contrast, at concentrations of
SMX between 0.5 and 1 mg/mL, EHY1 complemented with
P. jiroveci DHPS harbouring either one or no mutation was
more sensitive than the YH1 parent strain.
Discussion
Sulfamethoxazole, which targets the DHPS enzyme, remains
a major component of PCP treatment and prophylaxis.
A correlation between mutation(s) in the P. jiroveci DHPS
gene and resistance to SMX has been suggested by several
surveys [16–18]. However, the inability to culture P. jiroveci
in a standardized culture system prevents routine suscepti-
bility testing and detection of drug resistance. To address
this question, an alternative strategy using S. cerevisiae was
thus designed. Indeed, S. cerevisiae is an easy and inexpen-
sive tool, commonly used for in vitro complementation stud-
ies, notably for testing inhibitors of heterologous enzymes
[27,28]. Recently, functional complementation of deleted
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FIG. 2. In vitro susceptibility of transformed Saccharomyces cerevisiae
strains against sulfamethoxazole (SMX) according to the dihydro-
pteroate synthase (DHPS) genotype. (A–D): EHY1 (DHPS-deficient)
transformed by the pcM189 vector harbouring (A) double mutated
(positions 165 and 171) Pneumocystis jiroveci DHPS; (B) position 165
mutated P. jiroveci DHPS; (C) position 171 mutated P. jiroveci; (D)
wild-type P. jiroveci DHPS; (E) YH1 (functional DHPS). Plates were
photographed after 2 days’ incubation at 30C.
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FIG. 3. In vitro sulfamethoxazole (SMX) susceptibility assay in YEPD liquid medium. Yeast strains YH1 [functional dihydropteroate synthase
(DHPS)] and EHY1 (DHPS-deficient) transformed with the different genotypes of Pneumocystis jiroveci DHPS WW-PjDHPS: wild-type P. jiroveci
DHPS; WM-PjDHPS: position 171 mutated P. jiroveci DHPS; MW-PjDHPS: position 165 mutated P. jiroveci DHPS; MM-PjDHPS: double mutated
(positions 165 and 171) P. jiroveci DHPS. Growth was measured by optical density at 595 mm 48 h after incubation at 30C. The error bars
indicate standard deviations of triplicate experiments.
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yeasts by Pneumocystis homologue genes has been obtained
for dihydrofolate synthase and brl1 (coding for a nuclear
envelope protein) genes [29,30]. Together with our data,
this supports the development of an S. cerevisiae model to
explore other biological characteristics of P. jiroveci until a
reliable in vitro culture becomes available [31]. In accor-
dance with previous studies showing the efficacy of other
sulfonamide derivatives against yeasts [28], we confirmed
the in vitro susceptibility of S. cerevisiae to SMX. We then
fully complemented a DHPS-deficient yeast strain with the
wild-type P. jiroveci DHPS gene, consistent with the high
level of conservation of this enzyme (73% similarity
between S. cerevisiae and P. jiroveci). Complementation was
successful for all four P. jiroveci DHPS alleles. However, the
response to SMX was different, according to which P. jiroveci
DHPS allele was expressed. Pneumocystis jiroveci DHPS with
the double mutation was associated with lower suscep-
tibility to SMX, an observation supported by assays
performed either on solid medium or in liquid medium. It
is noteworthy that multiple point mutations in the Plasmo-
dium falciparum DHPS gene are required for the induction
of resistance to sulfa drugs [32,33]. This may be due to
critical changes in the structure of the protein leading to an
altered interaction with the substrate, here, the sulfa drug.
Our findings strengthen the results of previous studies
that used either E. coli or S. cerevisiae as models and site-
directed mutagenized DHPS to address the question of
resistance to sulfa drugs [19,34]. Similarly, in E. coli, using a
heterologous DHPS construction consisting of DNA
fragments coding for the first 33 amino acids of the yeast
DHPS fused to the different alleles of P. jiroveci DHPS, double
mutation resulted in MICs threefold higher than wild-type
DHPS [35].
In contrast, complementation by chromosomal integration
of a fragment of the S. cerevisiae FOL1 gene, previously
mutagenized, into a DHPS-knockout yeast strain resulted in
a requirement of pABA for growth, evidence of reduced
susceptibility to sulfa drugs, but in this case associated with
hypersensitivity to SMX [20].
Our study differed from these studies by the use of P. jiro-
veci DHPS genes obtained directly from clinical specimens.
Contrary to previous studies, this was not associated with
an auxotrophy for pABA, allowing easier interpretation of
the susceptibility tests that clearly demonstrate a decrease of
SMX susceptibility in the case of double mutation in the
P. jiroveci DHPS. This was not an artefact result due to a
growth defect of the more susceptible strains, since all
constructed strains exhibited a growth rate generally similar
to that of the DHPS-functional parent strain (data not
shown).
The clinical impact of these mutations is still controversial.
In Europe, the prevalence of the double mutated genotype
remains low (<3%), whereas prevalence as high as 40% has
been reported in the USA [36–38]. Some studies did not find
any link between DHPS mutations and treatment setting or
clinical outcome [5,39], whereas a threefold increase in mor-
tality rate has been demonstrated for patients infected with
Pneumocystis harbouring a DHPS mutation, compared with
those infected with wild type-DHPS Pneumocystis [16].
Pharmacokinetic properties (notably related to drug
dosage) and pharmacodynamic properties of therapeutic
molecules may influence the clinical results. Furthermore,
the correlation between in vitro susceptibility tests and clini-
cal outcome is often considered to be poorly predictive of
opportunistic fungal infections, the prognosis being related
mainly to host immune status. However, several surveys
have highlighted a correlation between the presence of
DHPS mutations and prophylaxis with sulfa drugs [40–42].
Moreover, a double mutated allele is the predominant P. jiro-
veci DHPS genotype found in patients experiencing sulfa-drug
prophylaxis failure [11,39,43], suggesting the existence of a
selective pressure on P. jiroveci organisms.
Our results confirm the importance of DHPS genotyping of
P. jiroveci to establish more clearly a possible link between
double mutation in the P. jiroveci DHPS gene and clinical
outcome according to therapy. A positive correlation would
prompt the use of higher doses of SMX or the use of alterna-
tive therapies.
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